Pasithea Therapeutics (KTTA) Other Non-Current Liabilities (2021 - 2026)
Pasithea Therapeutics (KTTA) posted Other Non-Current Liabilities of $52966.0 for Q1 2026, up 13.0% sequentially from $46871.0 in Q4 2025, and down 37.91% YoY from $85305.0 in Q1 2025.
Pasithea Therapeutics (KTTA) Other Non-Current Liabilities (2021 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Other Non-Current Liabilities for 6 years, with the latest figure at $52966.0 in Q1 2026.
- Quarterly Other Non-Current Liabilities fell 37.91% year-over-year to $52966.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52966.0 (down 37.91% YoY) and the FY2025 annual result came in at $46871.0, down 71.1% from the prior year.
- Other Non-Current Liabilities advanced to $52966.0 in Q1 2026 per KTTA's latest filing, from $46871.0 in the prior quarter.
- Over five years, Other Non-Current Liabilities peaked at $667503.0 in Q1 2022 and troughed at $29059.0 in Q3 2023.
- A 5-year average of $164761.4 and a median of $93272.0 in 2024 frame the typical range for Other Non-Current Liabilities.
- The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities slumped 95.0% in 2023, then jumped 462.92% in 2024.
- Over 5 years, Other Non-Current Liabilities stood at $140611.0 in 2022, then slumped by 40.0% to $84366.0 in 2023, then surged by 92.22% to $162172.0 in 2024, then plunged by 71.1% to $46871.0 in 2025, then rose by 13.0% to $52966.0 in 2026.
- According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $52966.0, $46871.0, and $46871.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Pasithea Therapeutics | 16.97 Mn | 16.97 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52,966.00 |
| Dec 31, 2025 | 46,871.00 |
| Sep 30, 2025 | 46,871.00 |
| Jun 30, 2025 | 93,741.00 |
| Mar 31, 2025 | 85,305.00 |
| Dec 31, 2024 | 162,172.00 |
| Sep 30, 2024 | 163,578.00 |
| Jun 30, 2024 | 93,272.00 |
| Mar 31, 2024 | 57,650.00 |
| Dec 31, 2023 | 84,366.00 |
| Sep 30, 2023 | 29,059.00 |
| Jun 30, 2023 | 74,055.00 |
| Mar 31, 2023 | 176,000.00 |
| Dec 31, 2022 | 140,611.00 |
| Sep 30, 2022 | 581,120.00 |
| Jun 30, 2022 | 245,803.00 |
| Mar 31, 2022 | 667,503.00 |
| Dec 31, 2021 | 1.45 Mn |
| Sep 30, 2021 | 4.04 Mn |